secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0001564590-23-003792
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences reports Q4/FY 2022 net loss $42.4M; cash $24.8M; phase 3/2 trial data due Q2 2023
--------------------------------------------------------------------------------

- Cash, cash equivalents, and restricted cash totaled $24.8M as of Dec 31, 2022.
- Net loss for FY 2022 was $42.4M; Q4 2022 net loss $11.2M.
- Phase 3 ORCA-3 and Phase 2 ORCA-V1 top-line results expected in Q2 2023.
- Closed $18.9M private placement in Nov 2022 to fund trials and working capital.
- USPTO granted patent for cytisinicline mesylate salt formulation, expiring 2042.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000156459023003792/0001564590-23-003792-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000156459023003792/achv-8k_20230316.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-003792

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer